计算机科学
过程开发
风险分析(工程)
生化工程
过程(计算)
蛋白质稳定性
理论(学习稳定性)
单克隆抗体
临床实习
计算生物学
开发(拓扑)
药物发现
纳米技术
数据科学
铅(地质)
作者
Tim Menzen,Kristian Le Vay,Andrea Arsiccio,Constanze Helbig,Kerstin Hausmann,Thomas Pabstmann,Andrea Hawe
标识
DOI:10.1016/j.xphs.2025.104054
摘要
Formulation development aims at finding the most stabilizing conditions for a particular therapeutic protein molecule. Typically, various combinations of buffer type, pH, and additional excipients are experimentally tested at different concentrations in a laborious process to identify a suitable formulation. It is therefore tempting to use a platform approach and apply previously successful formulations to similar proteins, particularly for monoclonal antibodies (mAbs), which typically only differ in their antigen-binding region. Such a platform approach comes with the risk that the protein is insufficiently stable in the platform formulation to be suitable for first-in-human studies. Formulatability assessment closes a gap between discovery and pre-clinical formulation development by taking the protein's physicochemical stability and formulation conditions into consideration. The evaluation of a protein candidate's biophysical properties during formulatability assessment provides data to facilitate the decision as to whether the molecule may be suitable for a platform formulation, or if an extended pre-formulation screening is required in order to identify conditions that promote conformational, colloidal, or chemical stability of the protein. We discuss how formulation scientists can put a risk-based mAb platform formulation approach into practice, including formulatability assessment, systematic pre-formulation and storage stability studies with platform analytical methods.
科研通智能强力驱动
Strongly Powered by AbleSci AI